Literature DB >> 25053572

Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.

Kenneth E Fleisher1, Roy A Raad2, Rajan Rakheja3, Vikas Gupta4, King Chong Chan5, Kent P Friedman6, Karen A Mourtzikos7, Malvin Janal8, Robert S Glickman9.   

Abstract

PURPOSE: Imaging is important to identify subclinical changes and for treatment planning in patients with osteonecrosis of the jaw (ONJ) exposed to antiresorptive therapy. The aim of this study was to compare the findings at radiography with those at fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography (CT) for patients with ONJ related to antiresorptive therapy.
MATERIALS AND METHODS: A cross-sectional retrospective analysis of patients with clinically identified ONJ lesions of the mandible was performed. Two imaging modalities were evaluated for each patient: plain radiography (ie, panoramic or periapical) and FDG PET/CT with 1-mm sections. Outcome variables for the radiographic findings were osteolytic and osteosclerotic bone changes. Outcome variables for FDG PET/CT images were localization of FDG uptake. Maximum standard uptake values (SUVmax) of abnormal FDG jaw uptake were recorded, in addition to the mean SUV of the contralateral normal mandible, and used to calculate the target-to-background ratio. Radiographic changes and FDG uptake were classified as local (ie, corresponding to exposed cortical bone) or diffuse (ie, local changes and changes extending beyond the margins of exposed bone) for each imaging technique. Local and diffuse changes detected by each imaging modality were described and the difference in detection was compared with the McNemar test.
RESULTS: Twenty-three patients with 25 clinically identified ONJ lesions were analyzed using radiography and FDG PET/CT. Differences were found in how radiography and FDG PET/CT detect local and diffuse changes associated with ONJ. Radiography showed local changes in 17 patients (68%), diffuse changes in 3 patients (12%), and no changes in 5 patients (20%), whereas FDG PET/CT imaging showed local changes in 17 patients (68%) and diffuse changes in 8 patients (32%). The McNemar test indicated that FDG PET/CT imaging was less likely to miss a lesion (P < .001). Mean SUVmax was 6.59, and the mean target-to-background ratio was 5.37.
CONCLUSION: The results of this study show that FDG PET/CT detects local and diffuse metabolic changes that may not be represented by plain radiography for patients with ONJ related to antiresorptive therapy. The target-to-background ratio allowed the discrimination between ONJ lesions and background changes. Future studies are necessary to determine whether FDG PET/CT can determine risk and facilitate management of ONJ.
Copyright © 2014 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25053572     DOI: 10.1016/j.joms.2014.04.017

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  9 in total

1.  Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis.

Authors:  Kamile Leonardi Dutra; Letícia Fernanda Haas; Glaucia S Zimmermann; Gilberto Melo; Mariana Comparotto Minamisako; Carlos Flores-Mir; Márcio Corrêa
Journal:  Dentomaxillofac Radiol       Date:  2018-11-07       Impact factor: 2.419

Review 2.  Chemical and Radiation-Associated Jaw Lesions.

Authors:  Temitope T Omolehinwa; Sunday O Akintoye
Journal:  Dent Clin North Am       Date:  2016-01

Review 3.  Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.

Authors:  Pongsapak Wongratwanich; Kiichi Shimabukuro; Masaru Konishi; Toshikazu Nagasaki; Masahiko Ohtsuka; Yoshikazu Suei; Takashi Nakamoto; Rinus G Verdonschot; Tomohiko Kanesaki; Pipop Sutthiprapaporn; Naoya Kakimoto
Journal:  Dentomaxillofac Radiol       Date:  2021-01-15       Impact factor: 3.525

Review 4.  Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ).

Authors:  Britt-Isabelle Berg; Andreas A Mueller; Marcello Augello; Scott Berg; Claude Jaquiéry
Journal:  Dent J (Basel)       Date:  2016-09-02

5.  Use of bone scintigraphy in the early diagnosis of bisphosphonate related osteonecrosis of the jaw. Case report and review of the literature.

Authors:  José-Darío Sánchez-López; Paolo Cariati; Jacobo Cambil-Martin; Mercedes Villegas-Calvo; María-Luisa Moreno-Martin
Journal:  J Clin Exp Dent       Date:  2018-12-01

Review 6.  Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and 18F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication).

Authors:  Satoru Watanabe; Kenichi Nakajima; Seigo Kinuya
Journal:  Jpn Dent Sci Rev       Date:  2019-03-20

7.  18F-Fluoride PET/CT Imaging of Medication-Related Osteonecrosis of the Jaw in Conservative Treatment-A Case Report.

Authors:  Christian Philipp Reinert; Christina Pfannenberg; Sergios Gatidis; Christian la Fougère; Konstantin Nikolaou; Sebastian Hoefert
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

8.  Potential role of post-treatment follow-up FDG-PET CT to detect mandibular osteoradionecrosis: A case report.

Authors:  Masaya Akashi; Satoshi Wanifuchi; Junya Kusumoto; Megumi Kishimoto; Yasumasa Kakei; Kazunobu Hashikawa; Takahide Komori
Journal:  Mol Clin Oncol       Date:  2017-11-02

9.  Predictive factors for refractory stage I and II anti-resorptive agent-related osteonecrosis of the jaw.

Authors:  Takahiro Shimizu; Mai Kim; Trang Thuy Dam; Jun Kurihara; Masaru Ogawa; Takaya Makiguchi; Satoshi Yokoo
Journal:  Oral Radiol       Date:  2021-07-03       Impact factor: 1.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.